A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia

Schizophrenia Research

Volumn 37, Issue 1, 1999, Pages 1-11

  Lee, Myung A ^a   Jayathilake, Karuna ^a   Meltzer, Herbert Y ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Clozapine; Cognition; Fluency; Schizophrenia; Typical neuroleptic

Indexed keywords

ATENOLOL; BENZATROPINE; CLOZAPINE; DESIPRAMINE; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MOLINDONE; NEUROLEPTIC AGENT; PERPHENAZINE; THIORIDAZINE; VERAPAMIL;

ADULT; ARTICLE; COGNITION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; LEARNING; MAJOR CLINICAL STUDY; MALE; MAZE TEST; PERSONALITY TEST; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RECALL; SCHIZOPHRENIA; VERBAL BEHAVIOR;

ADULT; CLOZAPINE; COGNITION; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0033522429     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(98)00145-5     Document Type: Article

References (72)

1. American Psychiatric Association, 1987. Diagnostic and Statistical Manual of Mental Disorders, 3rd ed., revised (DSM-III-R). American Psychiatric Press, Washington, DC.
2. Baldessarini R.J., Frankenberg F.F. Clozapine; a novel antipsychotic agent. New Engl. J. Med. 324:1991;746-754.
3. Benton A.L. Differential behavioral effects in frontal lobe disease. Neuropsychologia. 6:1968;53-60.
4. Benton, A.L., Hamsher, K., Verney, N.R., Spreen, D., 1983. Contributions to Neuropsychological Assessment. Oxford University Press, New York.
5. Berg E.A. A simple objective test for measuring flexibility in thinking. J. Gen. Psychol. 39:1948;15-22.
6. Bilder R.M., Lipschultz-Broch L., Reiter G., Mayerhoff D., Loebel A., Degreef G., Ashtari M., Lieberman J.A. Neuropsychological studies of first episode schizophrenia. Schizophr. Res. 4:1991;381-382.
7. Bilder R.M., Lipschutz-Broch L., Reiter G., Geisler S.H., Mayerhoff D.I., Lieberman J.A. Intellectual deficits in first-episode schizophrenia: evidence for progressive deterioration. Schizophr. Bull. 18:1992;437-448.
8. Bilder R.M., Turkel E., Lipschutz-Broch L., Lieberman J.A. Antipsychotic medication effects on neuropsychological functions. Psychopharmacol. Bull. 28:1992;353-366.
9. Bilder R.M., Lieberman J.A., Kim Y., Alvir J.M., Reiter G. Methylphenidate and neuroleptic effects on oral word production in schizophrenia. Neuropsychiatry Neuropharmacol. Behav. Neurol. 5:1992;262-271.
10. Borkowski J.G., Benton A.L., Spreen O. Word fluency and brain damage. Neuropsychologia. 5:1967;135-140.
11. Braff D.L., Heaton R., Kuck J., Cullum M., Moranville J., Grant I., Zisook S. The generalized pattern of neuropsychological deficits in outpatients with chronic schizophrenia with heterogenous Wisconsin Card Sorting Test results. Arch. Gen. Psychiatry. 48:1991;891-898.
12. Buchanan R.W., Holstein C., Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol. Psychiatry. 36:1994;717-725.
13. Buschke H., Fuld P.A. Evaluating storage, retention and retrieval in disordered memory and learning. Neurology. 11:1974;1019-1025.
14. Cassens G., Inglis A.K., Appelbaum P.S., Gutheil T.G. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr. Bull. 16:1990;477-499.
15. Cohen J.D., Forman D.S., Braver T.S., Casey B.J., Servan-Schreiber D., Noll D.C. Activation of the prefrontal cortex in a nonspatial working memory task with functional MRI. Hum. Brain Mapp. 1:1994;293-304.
16. Daniel D.G., Goldberg T.E., Weinberger D.R., Kleinman J.E., Pickar D., Lubick L.J., Williams T.S. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. Am. J. Psychiatry. 153:1996;417-419.
17. Endicott J., Spitzer R.L. A diagnostic interview. The schedule for affective disorders and schizophrenia. Arch. Gen. Psychiatry. 35:1978;837-844.
18. Friedman L., Knutson L., Shurell M., Meltzer H.Y. Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia. Biol. Psychiatry. 29:1991;865-877.
19. Frith C.D., Friston K.J., Liddle P.F., Frackowiak R.S.J. A PET study of word finding. Neuropsychologia. 29:1991;1137-1148.
20. Fujii D.E., Ahmed I., Jokumsen M., Compton J.M. The effects of clozapine on cognitive function in treatment-resistant schizophrenic patients. J. Neuropsychiatry Clin. Neurosci. 9:1997;240-245.
21. Galletly et al., 1996.
22. Galletly C.A., Clark C.R., McFarlane A.C., Weber D.L. Relationships between changes in symptoms ratings, neuropsychological test performance and quality of life in schizophrenic patients treated with clozapine. Psychiatry Res. 72:1997;161-166.
23. Gilbertson M.W., van Kammen D.P. Recent and remote memory dissociation: medication effects and hippocampal function in schizophrenia. Biol. Psychiatry. 42:1997;585-595.
24. Goldberg T.E., Gold J.M., Greenberg R., Griffin S., Schulz S.C., Pickar D., Kleinman J.E., Weinberger D.R. Contrasts between patients with affective disorder and patients with schizophrenia on a neuropsychological test battery. Am. J. Psychiatry. 150:1993;1355-1362.
25. Goldberg T.E., Greenberg R.D., Griffin S.J., Gold J.M., Kleinman J.E., Pickar D., Schulz S.C., Weinberger D.R. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. J. Psychiatry. 162:1993;43-48.
26. Grace et al., 1995.
27. Grace J., Bellus S.B., Raulin M.L., Herz M.I., Priest B.L., Brenner V., Donnelly K., Smith P., Gunn S. Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning. Psychiatr. Serv. 47:1996;41-45.
28. Guy, W. (Ed.), 1976. ECDEU Assessment Manual for Psychopharmacology. Publication ADM 76-338. United States Department of Health, Education, and Welfare, Washington, DC, pp. 534-537.
29. Hagger C., Buckley P., Kenny J.T., Friedman L., Ubogy D., Meltzer H.Y. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol. Psychiatry. 34:1993;702-712.
30. Heaton R., Paulsen J.S., McAdams L.A., Kuck J., Zisook S., Braff D., Harris M.J., Jeste D.V. Neuropsychological deficits in schizophrenics: relationships to age, chronicity and dementia. Arch. Gen. Psychiatry. 51:1994;469-476.
31. Hoff A.L., Riordan H., O'Donnell D.W., Morris L., DeLisi L.E. Neuropsychological functioning of first-episode schizophreniform patients. Am. J. Psychiatry. 149:1992;898-903.
32. Hoff et al., 1995.
33. Hoff A.L., Faustman W.O., Wienke M., Espinoza S., Costa M., Wolkowitz O., Csernansky J.G. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology. 15:1996;361-369.
34. Jennrich R.L., Schuehter M.D. Unbalanced repeated-measures models with structured covariance matrices. Biometrics. 42:1985;805-820.
35. Kane, J., Honigfeld, G., Singer, J., Meltzer, H.Y., the Clozaril Collaborative Study Group, 1988. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine/benztropine. Arch. Gen. Psychiatry 45: 789-796.
36. Kenny J.T., Meltzer H.Y. Attention and higher cortical functions in schizophrenia. J. Neuropsychiatry. 3:1991;269-275.
37. King D.J. The effect of neuroleptics on cognitive and psychomotor function. J. Psychiatry. 157:1990;799-811.
38. Kirk, R.E., 1982. Experimental Design. Procedure for the Behavioral Sciences, 2nd ed. Brooks/Cole, Belmont, CA.
39. Lee M.A., Thompson P.A., Meltzer H.Y. Effects of clozapine on cognitive function in schizophrenia. J. Clin. Psychiatry. 55(Suppl B):1994;82-87.
40. Lindenmayer, J.P., Iskander, A., Park, M., Apergi, F.S., Czobor, P., Smith, R., Allan, D., in press. Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenics: a prospective study. J. Clin Psychiatry.
41. Littell, R.C., Milliken, G.A., Stroup, W.W., Wolfinger, R.D., 1996. SAS System for Mixed Models. SAS Institute, Cary, NC.
42. McCarthy G., Blamire A.M., Rothman D.L., Gruetter R., Shulman R.G. Echo planar magnetic resonance imaging studies of frontal cortex activation during word generation in humans. Proc. Natl. Acad. Sci. USA. 90:1993;4952-4956.
43. Meltzer H.Y., Ranjan R., Lee M.A., Kennedy J. Emerging clinical uses of clozapine. Rev. Contemp. Pharmacother. 6:1995;187-196.
44. Meltzer, H.Y., McGurk, S.R., in press. The effect of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophr. Bull.
45. Meyer-Lindenberg A., Gruppe H., Bauer U., Lis S., Krieger S., Gallhofer B. Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study. Pharmacopsychiatry. 30:1997;35-42.
46. Miller J.L., Hiley C.R. Anti-dopaminergic and anti-muscarinic effects of dibenzodiazepine. Naunyn-Schmiedeberg's Arch. Pharmacol. 292:1976;289-293.
47. Miller E. Verbal fluency as a function of a measure of verbal intelligence and in relation to different types of cerebral pathology. Br. J. Clin. Psychol. 23:1984;53-57.
48. Milner B. Interhemispheric differences in the localization of psychological processes in man. Br. Med. Bull. 27:1971;272-277.
49. Murphy B.L., Arnsten A.F.T., Goldman-Rakic P.S., Roth R.H. Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys. Proc. Natl. Acad. Sci. USA. 93:1996;1325-1329.
50. Murphy B.L., Roth R.H., Arnsten A.F.T. Clozapine reverses the spatial working memory deficits induced by FG7142 in monkeys. Neuropsychopharmacology. 16:1997;433-437.
51. Nestor P.G., Faux S.F., McCarley R.W., Sands S.F., Horvath T.B., Peterson A. Neuroleptics improve sustained attention in schizophrenia: a study using signal detection theory. Neuropsychopharmacology. 4:1991;145-149.
52. Newcomb, F., 1969. Missile Wounds of the Brain: A Study of Psychological Deficits. Oxford University Press, London.
53. Olianas M.C., Maullu C., Onali P. Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor. Br. J. Pharmacol. 122:1997;401-408.
54. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale. Psychol. Rep. 10:1962;799-812.
55. Parada M.A., Hernandez L., Puig de Parada M., Rada P., Murzi E. Selective actions of acute systemic clozapine on acetylcholine release in the rat prefrontal cortex by reference to the nucleus accumbens and striatum. J. Pharmacol. Exp. Ther. 281:1997;582-588.
56. Peterson L.R., Peterson M.J. Short-term retention of individual verbal items. J. Exp. Psychol. 58:1959;193-198.
57. Petrides M., Alivisatos B., Meyer E., Evans A.C. Functional activiation of the human frontal cortex during the performance of verbal working memory tasks. Proc. Natl. Acad. Sci USA. 90:1993;878-882.
58. Saykin A.J., Shtasel D.L., Gur R.E., Kester D.B., Mozley L.H., Stafiniak P., Gur R.C. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch. Gen. Psychiatry. 51:1994;124-131.
59. Simpson G.M., Angus J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. 212(Suppl.):1970;11-19.
60. Snyder S.H., Yamamura H.I. Antidepressants and the muscarinic acetylcholine receptor. Arch. Gen. Psychiatry. 34:1977;236-239.
61. Spohn H.E., Strauss M.E. Relation of neuroleptic and anticholinergic medication to cognitive function in schizophrenia. J. Abnorm. Psychol. 98:1989;367-380.
62. Sweeney J.A., Haas G.L., Keilp J.G., Long M. Evaluation of the stability of neuropsychological functioning after acute episodes of schizophrenia: one year follow-up study. Psychiatry Res. 38:1991;63-76.
63. Sweeney J.A., Haas G.L., Li S. Neuropsychological and eye movement abnormalities in first-episode and chronic schizophrenia. Schizophr. Bull. 18:1992;283-293.
64. Talland, G.A., 1965. Deranged Memory. Academic Press, New York, NY.
65. Wechsler, D., 1974. WISC-R Manual. Wechsler Intelligence Scale for Children - Revised. Psychological Corporation, New York, NY.
66. Wechsler, D., 1981. WAIS-R Manual. Wechsler Adult Intelligence Scale - Revised. Psychological Corporation, New York, NY.
67. Weinberger D.R., Berman K.F., Illowsky B.P. Physiological dysfunction of dorso-lateral prefrontal cortex in schizophrenia: III. A new cohort and evidence for a monoaminergic mechanism. Arch. Gen. Psychiatry. 45:1988;609-615.
68. Williams G.V., Goldman-Rakic P.S. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature. 376:1995;572-575.
69. Wyatt R.J., Green M.F., Turma A.H. Long-term morbidity associated with delayed treatment of first admission, schizophrenic patients: a reanalysis of the Camarillo State Hospital data. Psychol. Med. 27:1997;261-268.
70. Yurgelun-Todd D.A., Watermaux C.M., Cohen B.M., Gruber S.A., English C.D., Renshaw P.F. Functional magnetic resonance imaging of schizophrenic patients and comparison subjects during word production. Am. J. Psychiatry. 153:1996;200-205.
71. Zahn et al., 1994.
72. 4 receptor agonist. Eur. J. Pharmacol. 269:1994;R1-R2.